Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease

被引:22
|
作者
Yoon, Hyung Ho [1 ]
Min, Joongkee [1 ]
Hwang, Eunmi [2 ,3 ]
Lee, C. Justin [2 ,3 ]
Suh, Jun-Kyo Francis [4 ]
Hwang, Onyou [5 ]
Jeon, Sang Ryong [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol Surg, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
[2] Korea Inst Sci & Technol, Ctr Neural Sci, Seoul, South Korea
[3] Korea Inst Sci & Technol, WCI Ctr Funct Connect, Seoul, South Korea
[4] Korea Inst Sci & Technol, Ctr Bion, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Deep brain stimulation; Halorhodopsin; Levodopa-induced dyskinesia; Optogenetics; Subthalamic nucleus; HIGH-FREQUENCY STIMULATION; DEEP BRAIN-STIMULATION; BASAL GANGLIA; REPLACEMENT; MECHANISMS; AKINESIA; CORTEX;
D O I
10.1159/000442891
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: The inhibition of neuronal activity by electrical deep brain stimulation is one of the mechanisms explaining the amelioration of levodopa-induced dyskinesia. However, electrical deep brain stimulation cannot specifically activate or inactivate selected types of neurons. Objectives: We applied optogenetics as an alternative treatment to deep brain stimulation for levodopa-induced dyskinesia, and also to confirm that the mechanism of levodopa-induced dyskinesia amelioration by subthalamic nucleus deep brain stimulation is mediated through neuronal inhibition. Methods: 6-hydroxydopamine-induced hemiparkinsonian rats received injections of hSynapsin1-NpHR-YFP adeno-associated virus (AAV) or hSynapsinl-YFP AAV. Two weeks after viral injections, all rats were treated with daily injections of levodopa. Then, the optic fiber was implanted into the ipsilateral subthalamic nucleus. We performed various behavioral tests to evaluate the changes in levodopa-induced dyskinesias after optogenetic expression and illumination in the subthalamic nucleus. Results: The behavioral tests revealed that optical inhibition of the subthalamic nucleus significantly ameliorated levodopa-induced dyskinesia by reducing the duration of the dyskinesias as well as the severity of axial dyskinesia. Conclusions: These findings will provide a useful foundation for the future development of optogenetic modulation systems that could be considered as an approach to dyskinesia therapy. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:41 / 53
页数:13
相关论文
共 50 条
  • [21] Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
    Metman, LV
    Del Dotto, P
    Natté, R
    van den Munckhof, P
    Chase, TN
    NEUROLOGY, 1998, 51 (01) : 203 - 206
  • [22] Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
    Stathis, P.
    Konitsiotis, S.
    Tagaris, G.
    Peterson, D.
    MOVEMENT DISORDERS, 2011, 26 (02) : 264 - 270
  • [23] Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease
    Hoff, JI
    vander Plas, AA
    Wagemans, EAH
    van Hilten, JJ
    MOVEMENT DISORDERS, 2001, 16 (01) : 58 - 61
  • [24] Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease
    Merims, D
    Ziv, I
    Djaldetti, R
    Melamed, E
    LANCET, 1999, 353 (9166): : 1764 - 1765
  • [25] Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model
    Obeso, JA
    Rodriguez-Oroz, MC
    Rodriguez, M
    DeLong, MR
    Olanow, CW
    ANNALS OF NEUROLOGY, 2000, 47 (04) : S22 - S34
  • [26] Risk factors for levodopa-induced dyskinesias in Parkinson’s disease
    F. Grandas
    Maria Luisa Galiano
    Cesar Tabernero
    Journal of Neurology, 1999, 246 : 1127 - 1133
  • [27] Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
    Calabresi, Paolo
    Standaert, David G.
    NEUROBIOLOGY OF DISEASE, 2019, 132
  • [28] Future scenarios for levodopa-induced dyskinesias in Parkinson's disease
    Cerasa, Antonio
    Koch, Giacomo
    Fasano, Alfonso
    Morgante, Francesca
    FRONTIERS IN NEUROLOGY, 2015, 6
  • [29] Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease
    Cheshire, Perdita A.
    Williams, David R.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (03) : 343 - 348
  • [30] Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?
    Bejjani, BP
    Arnulf, I
    Demeret, S
    Damier, P
    Bonnet, AM
    Houeto, JL
    Agid, Y
    ANNALS OF NEUROLOGY, 2000, 47 (05) : 655 - 658